Search Results for "Mesalamine Ibs"
Original Source: Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)
The purpose of this study is to find whether treating patients with diarrhea predominant Irritable Bowel Syndrome (IBS) with an anti-inflammatory drug called Mesalamine will help improve their symptoms of diarrhea, bloating and abdominal pain.
Matching Channels
None
Matching News
Delzicol mesalamine regulatory update
FDA Approves Warner Chilcott's New 400 Mg Mesalamine
ROCKAWAY (dpa-AFX) - Warner Chilcott Plc (WCRX) Tuesday said the United States Food and Drug Administration has approved its new 400 mg mesalamine product indicated for the treatment of ulcerative...
FDA approves Warner Delzicol ulcerative colitis therapy
The US FDA has approved Warner Chilcott's 400mg mesalamine product as new ulcerative colitis therapy, to be marketed as Delzicol.
Warner Chilcott Announces FDA Approval of New Ulcerative Colitis Product Delzicol
DUBLIN, Ireland, Feb. 5, 2013 -- Warner Chilcott plc today announced that the United States Food and Drug Administration (FDA) has approved its new 400 mg mesalamine product indicated for the treatmen...
Shire prevails in US Lialda patent dispute with Watson
Ireland-headquartered drugmaker Shire's (LSE: SHP) subsidiary Shire Development has prevailed in its US litigation against three companies (now trading as Actavis: NYSE: ACT) in connection with their...
Altheus Therapeutics Announces First Patient in Phase 2 Ulcerative Colitis Trial of Zoenasa®
OKLAHOMA CITY, Aug. 28, 2012 /PRNewswire/ -- Altheus Therapeutics announced today it has randomized its first patient in a comparator-controlled Phase 2 efficacy study of Zoenasa®, a...
Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2013
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that presentations related to the investigation of two of the Company’s products are scheduled to take place during Dig...
Shire Wins Patent Trial Against Watson Concerning LIALDA®
PHILADELPHIA, May 9, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), announces that its subsidiary, Shire Development LLC, has prevailed in its litigation against Watson Pharmaceuticals Inc....
Matching PubMed Articles
Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis.
OBJECTIVES:Treatment with mesalamine to maintain endoscopic remission (mucosal healing) of ulcerative colitis (UC) has been shown to reduce the risk of relapse and is the recommended first-line mainte...
Mesalamine is the first line pharmacologic intervention for patients with ulcerative colitis, and recent epidemiologic studies have demonstrated a protective association between therapeutic use of the...
Ulcerative colitis (UC) is a chronic inflammatory disease that primarily affects the colonic mucosa. Mesalamine had been established as a first line drug for treating mild to moderate UC. A continued...
Expanding Applications: The Potential Usage of 5-Aminosalicylic Acid in Diverticular Disease.
Diverticular disease is a common bowel condition, the pathogenesis of which is incompletely understood. Acute exacerbations of diverticular disease usually require dietary changes, antibiotic therapy,...
BACKGROUND: Ulcerative colitis (UC) is a chronic relapsing and remitting idiopathic inflammatory bowel disorder. AIM: To evaluate once-daily mesalamine (mesalazine) granules (MG) for maintenance of re...
